Released Nov 8, 2012, during market hours
10-Q filed Nov 8, 2012, 39 days after period end · 0001193125-12-460243
Q3 2012 · 10-Q
Revenue$26.10M$26.10M −1.0% vs Q3 2011−8.4% vs Q2 2012
Net Income-$133.00K-$133.00K N/M vs Q3 2011N/M vs Q2 2012
EPS Diluted-$0.01-$0.01 — vs Q3 2011N/M vs Q2 2012
Gross Profit$11,969,000+0.8%
Operating Income$1,156,000+425.5%
Operating Cash Flowderived$2,503,000+106.9%
Margins · derived
Gross margin45.9%+0.8 pt vs Q3 2011
Operating margin4.4%+3.6 pt vs Q3 2011
Net margin-0.5%−0.6 pt vs Q3 2011
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2012 | Q3 2011 | Q3 2010 |
|---|---|---|---|
| Revenue | $26.10M | $26.38M | $26.45M |
| Net Income | -$133.00K | $28.00K | $12.73M |
| EPS Diluted | -$0.01 | $0.00 | $0.44 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Harvard Bioscience Inc · CIK 1123494 · Engraved from SEC EDGAR